Trevyent® is a drug-device combination product based on the PatchPump® technology (SteadyMed) and delivering treprostinil, a prostacyclin analogue.
Treprostinil delivered via the PatchPump technology is branded by our partner, SteadyMed, as TREVYENT . TREVYENT is a small, discreet, single-use (2 day) PatchPump. It is pre-filled with treprostinil and pre-programed at the correct delivery rate. PatchPump is equipped with sensors to provide patients audible and visual feedback on successful delivery and end of dosing.
Correvio entered into an exclusive license and supply agreement with SteadyMed to commercialize TREVYENT in Europe, Canada and the Middle East. European Marketing Authorization Application is planned to be filed with the EMA in 2017 for targeted launch date in 2018.
TREVYENT and PatchPump are trademarks owned by SteadyMed, Ltd. used under license.